Hims & Hers Health, Novo Nordisk
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health (HIMS – Research Report) today. The company’s shares closed yesterday at $20.76. According to TipRanks, ...
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...
Hims & Hers Health, Inc. HIMS delivered an earnings per share (EPS) of 32 cents in third-quarter 2024 against the ...
With a 77% revenue increase and a growing subscriber base, Hims & Hers Health Inc (HIMS) continues to innovate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback